Jennifer J Stevenson

US Patent:

20060002940, Jan 5, 2006

Filed:

Mar 14, 2003

Appl. No.:

10/507986

Inventors:

Jennifer Stevenson - San Diego CA, US

International Classification:

A61K 39/395
A61K 38/18

US Classification:

424178100, 514007000

Abstract:

Disclosed are methods and compositions for the treatment of a variety of illnesses by mimicking the outer leaflet of an apotic cell to allow for the induction of macrophage phagocytosis to serve as a means of removing unwanted and diseased cells using phosphatidylserine/cell-surface recognition domain conjugate compositions. Also disclosed are methods for making phosphatidylserine/cell-surface recognition domain conjugate compositions and their formulation for use in a various pharmaceutical applications including the treatment of diverse cancers and other maladies.

US Patent:

20070021378, Jan 25, 2007

Filed:

Jul 21, 2006

Appl. No.:

11/491388

Inventors:

Ajit Varki - Del Mar CA, US
Jennifer Stevenson - San Diego CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/727
G01N 33/567

US Classification:

514056000, 435007200

Abstract:

The disclosure provides in vitro and in vivo methods for identifying Heparins and Heparinoids that modulate the activity of selecting. The disclosure also provides Heparins and Heparinoids that modulate the activity of selecting. The identification and isolation of these heparin formulations has the potential to mediate a wide variety of pathologies mediated by P- and/or L-selectin, including hematogenous metastasis, diseases associated with inflammation (e.g., asthma, arthritis, allergic dermatitis), ischemia-reperfusion injury, or other pathologies such as sickle cell anemia. Selectin inhibition can be achieved at plasma concentrations lower than those that cause excessive anticoagulation or unwanted bleeding in a human subject.

US Patent:

20100081630, Apr 1, 2010

Filed:

Dec 3, 2009

Appl. No.:

12/630106

Inventors:

Ajit Varki - Del Mar CA, US
Jennifer L. Stevenson - Santa Clarita CA, US

International Classification:

A61K 31/727
C12Q 1/48

US Classification:

514 56, 435 15

Abstract:

The disclosure provides in vitro and in vivo methods for identifying Heparins and Heparinoids that modulate the activity of selectins. The disclosure also provides Heparins and Heparinoids that modulate the activity of selectins. The identification and isolation of these heparin formulations has the potential to mediate a wide variety of pathologies mediated by P- and/or L-selectin, including hematogenous metastasis, diseases associated with inflammation (e.g., asthma, arthritis, allergic dermatitis), ischemia-reperfusion injury, or other pathologies such as sickle cell anemia. Selectin inhibition can be achieved at plasma concentrations lower than those that cause excessive anticoagulation or unwanted bleeding in a human subject.